Zobrazeno 1 - 10
of 268
pro vyhledávání: '"Wieske, L."'
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 20, Pp 111-126 (2024)
Iris N van Doorn,1 Filip Eftimov,1 Luuk Wieske,1,2 Ivo N van Schaik,1,3 Camiel Verhamme1 1Department of Neurology and Clinical Neurophysiology, Amsterdam Neuroscience and University of Amsterdam, Amsterdam UMC, location AMC, the Netherlands; 2Departm
Externí odkaz:
https://doaj.org/article/ca3b5b2ce781446db905f2e26f774b76
Autor:
Wieske, L., Stalman, E.W., Dam, P.J.K. van, Kummer, L.Y., Steenhuis, M., Kempen, Z.L.E. van, Killestein, J., Volkers, A.G., Tas, S.W., Boekel, L., Wolbink, G., Kooi, A. van der, Raaphorst, J., Lowenberg, M., Takkenberg, B., D'Haens, G.R.A.M., Spuls, P.I., Bekkenk, M.W., Musters, A.H., Post, N.F., Bosma, A.L., Hilhorst, M.L., Vegting, Y., Bemelman, F.J., Voskuyl, A., Broens, B., Sanchez, A.P., Els, C.A.C.M. van, Wit, J. de, Rutgers, A., Leeuw, K. de, Horvath, B., Verschuuren, J.J.G.M., Ruiter, A.M., Ouwerkerk, L. van, Woude, D. van der, Allaart, C.F., Teng, Y.K.O., Paassen, P. van, Busch, M.H., Jallah, P.B.P., Brusse, E., Doorn, P.A. van, Baars, A.E., Hijnen, D., Schreurs, C.R.G., Pol, W.L. van der, Goedee, H.S., Keijzer, S., Keijser, J., Cristianawati, O., Brinke, A. ten, Verstegen, N.J.M., Zwinderman, K.A.H., Ham, S.M. van, Kuijpers, T.W., Rispens, T., Eftimov, F., T2B Immunity SARS CoV 2 Study Grp
Publikováno v:
Annals of the Rheumatic Diseases, 82(6). BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases. BMJ Publishing Group
Annals of the Rheumatic Diseases, 82(6):ard-2022-223464, 883-885. BMJ Publishing Group
Wieske, L, Stalman, E W, van Dam, P J K, Kummer, L Y, Steenhuis, M, van Kempen, Z L E, Killestein, J, Volkers, A G, Tas, S W, Boekel, L, Wolbink, G, van der Kooi, A, Raaphorst, J, Löwenberg, M, Takkenberg, B, D'Haens, G R A M, Spuls, P I, Bekkenk, M W, Musters, A H, Post, N F, Bosma, A L, Hilhorst, M L, Vegting, Y, Bemelman, F J, Voskuyl, A, Broens, B, Parra Sanchez, A, van Els, C C A C M, Wit, J D, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, J J G M, Ruiter, A M, van Ouwerkerk, L, van der Woude, D, Allaart, C F, Teng, Y K O, van Paassen, P, Busch, M H, Jallah, P B P, Brusse, E, van Doorn, P A, Baars, A E, Hijnen, D, Schreurs, C R G, van der Pol, W L, Goedee, H S, Keijzer, S, Keijser, J, Cristianawati, O, ten Brinke, A, Verstegen, N J M, Zwinderman, K A H, van Ham, S M, Kuijpers, T W, Rispens, T & Eftimov, F 2023, ' Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases ', Annals of the Rheumatic Diseases, vol. 82, no. 6, ard-2022-223464, pp. 883-885 . https://doi.org/10.1136/ard-2022-223464
Annals of the Rheumatic Diseases. BMJ Publishing Group
Annals of the Rheumatic Diseases, 82(6):ard-2022-223464, 883-885. BMJ Publishing Group
Wieske, L, Stalman, E W, van Dam, P J K, Kummer, L Y, Steenhuis, M, van Kempen, Z L E, Killestein, J, Volkers, A G, Tas, S W, Boekel, L, Wolbink, G, van der Kooi, A, Raaphorst, J, Löwenberg, M, Takkenberg, B, D'Haens, G R A M, Spuls, P I, Bekkenk, M W, Musters, A H, Post, N F, Bosma, A L, Hilhorst, M L, Vegting, Y, Bemelman, F J, Voskuyl, A, Broens, B, Parra Sanchez, A, van Els, C C A C M, Wit, J D, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, J J G M, Ruiter, A M, van Ouwerkerk, L, van der Woude, D, Allaart, C F, Teng, Y K O, van Paassen, P, Busch, M H, Jallah, P B P, Brusse, E, van Doorn, P A, Baars, A E, Hijnen, D, Schreurs, C R G, van der Pol, W L, Goedee, H S, Keijzer, S, Keijser, J, Cristianawati, O, ten Brinke, A, Verstegen, N J M, Zwinderman, K A H, van Ham, S M, Kuijpers, T W, Rispens, T & Eftimov, F 2023, ' Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases ', Annals of the Rheumatic Diseases, vol. 82, no. 6, ard-2022-223464, pp. 883-885 . https://doi.org/10.1136/ard-2022-223464
Patients with immune-mediated inflammatory diseases (IMIDs) may have impaired initial humoral responses after SARS-CoV-2 vaccination depending on the type of immunosuppression (ISP) used.1 It is largely unknown how antibody titres develop over time a
Autor:
Dam, K.P.J. van, Volkers, A.G., Wieske, L., Stalman, E.W., Kummer, L.Y.L., Kempen, Z.L.E. van, Killestein, J., Tas, S.W., Boekel, L., Wolbink, G.J., Kooi, A.J. van der, Raaphorst, J., Takkenberg, R.B., D'Haens, G.R.A.M.I., Spuls, P.W., Bekkenk, M.H., Musters, A.F., Post, N.L., Bosma, A.L., Hilhorst, M., Vegting, Y.J., Bemelman, F.E., Voskuyl, A., Broens, B., Sanchez, A.P., Els, C.A.C.M. van, Wit, J. de, Rutgers, A., Leeuw, K. de, Horvath, B., Verschuuren, J.J.G.M.M., Ruiter, A.M., Ouwerkerk, L. van, Woude, D. van der, Allaart, R.C.F., Teng, Y.K.O., Paassen, P.H. van, Busch, M.H., Jallah, P.B.P., Brusse, E., Doorn, P.A. van, Baars, A.E., Hijnen, D.J., Schreurs, C.R.G., Pol, W.L. van der, Goedee, H.S., Steenhuis, M., Keijzer, S., Keijser, J.B.D., Cristianawati, O., Brinke, A. ten, Verstegen, N.J.M., Ham, S.M. van, Rispens, T.W., Kuijpers, T., Lowenberg, M., Eftimov, F., TB2 Immunity Sars-Cov-2 Study Grp
Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::48e652b90d3e035b57aa8ad553b7a0eb
https://hdl.handle.net/1887/3630357
https://hdl.handle.net/1887/3630357
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kim, HW, Shim, SW, Zhao, AM, Roh, D, Han, HM, Middleton, S, Kim, W, Chung, S, Johnson, E, Prentice, J, Tacon, M, Koel-Simmelink, MJA, Wieske, L, Teunissen, CE, Bae, YC, Bennett, D, Rinaldi, S, Davies, A, Oh, SB
Traumatic peripheral nerve injuries are at high risk of neuropathic pain for which novel, effective therapies are urgently needed. Preclinical models of neuropathic pain typically involve irreversible ligation and/or nerve transection (neurotmesis).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::9e682860a74db39d5bd68bd8b00b53fc
https://ora.ox.ac.uk/objects/uuid:68cf6732-51d9-43e3-92ae-6ba9fc84abf7
https://ora.ox.ac.uk/objects/uuid:68cf6732-51d9-43e3-92ae-6ba9fc84abf7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
van Dam, K.P.J., Hogenboom, L., Stalman, E.W., Kummer, L.Y.L., Steenhuis, M., Keijser, J.B.D., ten Brinke, A., van Ham, S.M., Kuijpers, T.W., Rispens, T., Wieske, L., Eftimov, F., Strijbis, E.M., Killestein, J., van Kempen, Z.L.E.
Publikováno v:
Frontiers in neurology, 13:1032830. Frontiers Media S.A.
Frontiers in Neurology, 13:1032830. Frontiers Media S.A.
the T2B! immunity against SARS-CoV-2 study group 2022, ' Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination ', Frontiers in Neurology, vol. 13, 1032830 . https://doi.org/10.3389/fneur.2022.1032830
Frontiers in Neurology, 13:1032830. Frontiers Media S.A.
the T2B! immunity against SARS-CoV-2 study group 2022, ' Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination ', Frontiers in Neurology, vol. 13, 1032830 . https://doi.org/10.3389/fneur.2022.1032830
IntroductionDuring the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multiple sclerosis (MS), such as anti-CD20 therapies, have been associated with decreased humoral responses after SARS-CoV-2 vaccination. Hybrid immunity, re
Autor:
Volkov, M., Coppola, M., Huizinga, R., Eftimov, F., Huizinga, T.W.J., Kooi, A.J. van der, Oosten, L.E.M., Raaphorst, J., Rispens, T., Sciarrillo, R., Titulaer, M.J., Wieske, L., Toes, R.E.M., Huijbers, M.G.M., Schie, K.A. van, Woude, D. van der, T2B Consortium
Publikováno v:
T2B Consortium 2022, ' Comprehensive overview of autoantibody isotype and subclass distribution ', Journal of Allergy and Clinical Immunology, vol. 150, no. 5, pp. 999-1010 . https://doi.org/10.1016/j.jaci.2022.05.023
Journal of Allergy and Clinical Immunology, 150(5), 999-1010. MOSBY-ELSEVIER
Journal of Allergy and Clinical Immunology, 150(5), 999-1010. MOSBY-ELSEVIER
The presence of autoreactive antibodies is a hallmark of many autoimmune diseases. The effector functions of (auto)antibodies are determined by their constant domain, which defines the antibody isotype and subclass. The most prevalent isotype in seru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59192b959ff488b389e565b96a42d84b
https://hdl.handle.net/1887/3512518
https://hdl.handle.net/1887/3512518
Autor:
Stalman, E.W., Wieske, L., Dam, K.P.J. van, Kummer, L.Y., Kempen, Z.L.E. van, Killestein, J., Volkers, A.G., Tas, S.W., Boekel, L., Wolbink, G.J., Kooi, A.J. van der, Raaphorst, J., Lowenberg, M., Takkenberg, R.B., D'Haens, G.R.A.M., Spuls, P.I., Bekkenk, M.W., Musters, A.H., Post, N.F., Bosma, A.L., Hilhorst, M.L., Vegting, Y., Bemelman, F.J., Voskuyl, A.E., Broens, B., Sanchez, A.P., Els, C.A.C.M. van, Wit, J. de, Rutgers, A., Leeuw, K. de, Horvath, B., Verschuuren, J.J.G.M., Ruiter, A.M., Ouwerkerk, L. van, Woude, D. van der, Allaart, C.F., Teng, O.Y.K., Paassen, P. van, Busch, M.H., Jallah, P.B.P., Brusse, E., Doorn, P.A. van, Baars, A.E., Hijnen, D.J., Schreurs, C.R.G., Pol, W.L. van der, Goedee, H.S., Steenhuis, M., Keijzer, S., Keijser, J.B.D., Boogaard, A., Cristianawati, O., Brinke, A. ten, Verstegen, N.J.M., Zwinderman, K.A.H., Rispens, T., Ham, S.M. van, Kuijpers, T.W., Eftimov, F., T2B Immunity Against SARS Co
Publikováno v:
Annals of the Rheumatic Diseases, 81(12):222904, 1757-1766. BMJ Publishing Group
Annals of the rheumatic diseases, 81(12):222904, 1757-1766. BMJ Publishing Group
Annals of the Rheumatic Diseases, 81, 1757-1766. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 81(12), 1757-1766. BMJ Publishing Group
Stalman, E W, Wieske, L, van Dam, K P J, Kummer, L Y, van Kempen, Z L E, Killestein, J, Volkers, A G, Tas, S W, Boekel, L, Wolbink, G J, van der Kooi, A J, Raaphorst, J, Löwenberg, M, Takkenberg, R B, D'Haens, G R A M, Spuls, P I, Bekkenk, M W, Musters, A H, Post, N F, Bosma, A L, Hilhorst, M L, Vegting, Y, Bemelman, F J, Voskuyl, A E, Broens, B, Parra Sanchez, A, van Els, C C A C M, Wit, J D, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, J J G M, Ruiter, A M, van Ouwerkerk, L, van der Woude, D, Allaart, C F, Teng, O Y K, van Paassen, P, Busch, M H, Jallah, P B P, Brusse, E, van Doorn, P A, Baars, A E, Hijnen, D J, Schreurs, C R G, van der Pol, W L, Goedee, H S, Steenhuis, M, Keijzer, S, Keijser, J B D, Boogaard, A, Cristianawati, O, ten Brinke, A, Verstegen, N J M, Zwinderman, K A H, Rispens, T, van Ham, S M, Kuijpers, T W & Eftimov, F 2022, ' Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases ', Annals of the Rheumatic Diseases, vol. 81, no. 12, 222904, pp. 1757-1766 . https://doi.org/10.1136/ard-2022-222904
Annals of the Rheumatic Diseases, 81(12). BMJ PUBLISHING GROUP
Annals of the rheumatic diseases, 81(12):222904, 1757-1766. BMJ Publishing Group
Annals of the Rheumatic Diseases, 81, 1757-1766. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 81(12), 1757-1766. BMJ Publishing Group
Stalman, E W, Wieske, L, van Dam, K P J, Kummer, L Y, van Kempen, Z L E, Killestein, J, Volkers, A G, Tas, S W, Boekel, L, Wolbink, G J, van der Kooi, A J, Raaphorst, J, Löwenberg, M, Takkenberg, R B, D'Haens, G R A M, Spuls, P I, Bekkenk, M W, Musters, A H, Post, N F, Bosma, A L, Hilhorst, M L, Vegting, Y, Bemelman, F J, Voskuyl, A E, Broens, B, Parra Sanchez, A, van Els, C C A C M, Wit, J D, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, J J G M, Ruiter, A M, van Ouwerkerk, L, van der Woude, D, Allaart, C F, Teng, O Y K, van Paassen, P, Busch, M H, Jallah, P B P, Brusse, E, van Doorn, P A, Baars, A E, Hijnen, D J, Schreurs, C R G, van der Pol, W L, Goedee, H S, Steenhuis, M, Keijzer, S, Keijser, J B D, Boogaard, A, Cristianawati, O, ten Brinke, A, Verstegen, N J M, Zwinderman, K A H, Rispens, T, van Ham, S M, Kuijpers, T W & Eftimov, F 2022, ' Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases ', Annals of the Rheumatic Diseases, vol. 81, no. 12, 222904, pp. 1757-1766 . https://doi.org/10.1136/ard-2022-222904
Annals of the Rheumatic Diseases, 81(12). BMJ PUBLISHING GROUP
ObjectivesTo compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls, and to investigate determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19dc8c343aa3a7c58690faa029528df1
https://pure.eur.nl/en/publications/95be4c3a-8d51-4bec-a116-f9d40c9a985a
https://pure.eur.nl/en/publications/95be4c3a-8d51-4bec-a116-f9d40c9a985a